Female Founder
PhD Founder
VC-Backed FounderAbout
AI-designed gene editors programmed to deliver custom genetic cures at scale. Neoclease uses a patent-protected generative AI engine to design NeoMini gene editors—half the size of CRISPR-Cas9, with novel PAM recognition, zero off-targets, and 50x faster design cycles—aiming for a world without genetic disease.
Products
NeoMini Gene Editors
AI-generated, single-target gene editors that are half the size of CRISPR-Cas9, offering safer targeting, novel PAM recognition capabilities, zero off-target effects, and single AAV vector delivery. Designed in days using a generative AI engine trained on 3M+ sequences, capable of producing 100,000s of editor candidates per run with 50x faster discovery than traditional methods. Lead program targets LRRK2 disruption for Parkinson's disease treatment, with a pipeline expanding to uveal melanoma, cervical cancer, Huntington's disease, and Von Willebrand disease.
Click to read more